 Johnson & Johnson said it would begin testing an Ebola-virus vaccine in humans in January and could have 250,000 doses available in May, if health authorities deem it safe and promising enough to distribute more broadly.. There is no approved vaccine guarding against the deadly Ebola virus. The regimen under development by J&J in partnership with Denmark-based biotechnology company Bavarian Nordic would be the latest in a race to get vaccines into human testing—a crucial step in establishing whether an experimental...
  